These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 18226859)

  • 1. Targeted therapy for uveal melanoma.
    Triozzi PL; Eng C; Singh AD
    Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic implications of the emerging molecular biology of uveal melanoma.
    Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
    Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
    Economou MA
    Acta Ophthalmol; 2008 Dec; 86(8):930-1. PubMed ID: 19086934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
    Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
    Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.
    Bérubé M; Talbot M; Collin C; Paquet-Bouchard C; Germain L; Guérin SL; Petitclerc E
    Int J Oncol; 2005 Feb; 26(2):405-13. PubMed ID: 15645125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets in melanoma from angiogenesis to apoptosis.
    Sosman JA; Puzanov I
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
    Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
    Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic agents in uveal melanoma.
    Velho TR; Kapiteijn E; Jager MJ
    Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma.
    Hersey P
    Curr Opin Oncol; 2006 Mar; 18(2):189-96. PubMed ID: 16462190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveal melanoma: natural history and treatment options for metastatic disease.
    Wöll E; Bedikian A; Legha SS
    Melanoma Res; 1999 Dec; 9(6):575-81. PubMed ID: 10661768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
    Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
    Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Kinase inhibitors for the therapy of malignant melanoma].
    Becker JC; Schrama D; Bröcker EB; Houben R
    J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
    Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.